Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
338 people get ABIO articles and Market Currents by email alert.
Get email alerts on ABIO »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Drug Pipeline Pulse Check: A Challenging WeekResearch Recap • Tue, Mar 30, 2010 -
BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIOMike Havrilla • Tue, Nov 24, 2009 -
MercadoLibre: Bullish Options StrategyOption Maestro • Tue, Nov 24, 2009 -
-
-
-
-
-
There are no Transcripts on ABIO.
-
Gencaro™ Potential Efficacy in Preventing Atrial Fibrillation Paper Published in JACC: Heart FailureBusiness Wire (Jun 6, 2013)
-
Business Wire (Jun 5, 2013)
-
Business Wire (May 30, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Jan 29, 2013)
-
Business Wire (Oct 10, 2012)
-
Business Wire (Mar 26, 2012)
-
Business Wire (Dec 22, 2011)
-
at MarketWatch.com (Jun 9, 2011)
-
at MarketWatch.com (May 17, 2010)
ABIO vs. ETF Alternatives
Company Description
ARCA is a biopharmaceutical company whose principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate is GencaroTM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Thursday, May 30, 12:44 PM
Midday top 10 gainers: NBG +475%. CLWR +24%. NVE +22%. GV +19%. AIQ +17%. BVX +16%. CLSN +16%. AAU +15%. BAA +14%. GURE +13%.
Midday top 10 Losers: ABIO -30%. VIMC -20%. DLIA -13%. VRTB -11%. CVI -11%. HSOL -10%. WPCS -10%. AGII -9%. ARTX -8%. ALVR -8%. 5 Comments [On the Move] - Thursday, May 30, 9:29 AM Arca Biopharma (ABIO) plunges 30% premarket after announcing the pricing of a $20M equity offering. The company will issue ~125K preferred shares ($160/share, convertible to 100 shares of common, come with a warrant to purchase 50 shares of common at $1.60/share, immediately exercisable) with related warrants to buy a total of 6.25M common shares. (PR) Comment! [On the Move, Healthcare]
-
Thursday, May 30, 9:13 AM
Premarket gainers: NVE +22%. CLWR +20%. MY +15%. CLSN +13%. HSOL +12%. CPST +10%. EXPR +9%. LXRX +8%. BLDP +8%. VRNG +7%. RSOL +6%. WFR +6%. AMRN +6%. FSLR +6%. ALU +6%. EMC +6%. STP +5%. HIMX +5%. OCZ +5%.
Losers: ABIO -31%. BIG -9%. VNR -5%. BPFH -5%. 1 Comment [On the Move] -
Tuesday, April 23, 12:56 PM
Midday top 10 gainers: SCON +118%. MEMS +49%. CZR +29%. NFLX +24%. ARL +18%. CPLA +18%. VECO +17%. HSTM +17%. SANM +16%. ILMN +15%.
Midday top 10 losers: CPRX -15%. IIVI -13%. UNTK -13%. ABIO -13%. CASM -10%. EFUT -9%. GASS -9%. TAX -8%. SIFY -7%. USTR -7%. Comment! [On the Move] - Monday, April 22, 9:10 AM Premarket gainers: PWER +56%. ABIO +47%. MPR +40%. SILC +7%. SAND +5%. Comment! [On the Move]
- Monday, April 22, 8:43 AM Arca Biopharma (ABIO) soars 35% premarket. The company says it will collaborate with Medtronic (MDT) on a Phase 2b clinical trial for Gencaro, ABIO's lead developmental drug for the treatment of cardiac rhythm disorders. Comment! [Healthcare, On the Move]
- Tuesday, March 26, 12:12 PM Arca Biopharma (ABIO -6.2%) trades down today after the company filed a registration with the SEC to sell, from time to time, up to $20M of its stock and warrants. Comment! [Healthcare, On the Move]
-
Friday, March 8, 12:44 PM
Midday top 10 gainers: AQ +36%. GMXR +35%. MEET +22%. AMBA +22%. III +22%. ABIO +21%. PRGN +20%. BVSN +19%. P +18%. WG +17%.
Midday top 10 losers: SKUL -22%. PGRX -19%. SUTR -16%. TECUA -16%. FREE -15%. ANGO -13%. MXWL -13%. AVG -11%. ARCI -10%. OTIV -8%. Comment! [On the Move] - Tuesday, March 5, 10:50 AM ARCA Biopharma (ABIO +6.7%) trades up after announcing a 6-for-1 reverse split of its common stock, which became effective after the close yesterday, and trading on the NASDAQ on a split adjusted basis as of today. The reverse split reduces ABIO's number of shares issued and outstanding from approximately 19.1M shares to approximately 3.2M shares. Comment! [Healthcare, On the Move]
- Wednesday, January 30, 9:29 AM ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design clinical trial for its lead developmental drug, Gencaro, in atrial fibrillation. Medtronic (MDT) will be collaborating on the initial, phase 2B portion of the proposed trial. Comment! [Healthcare, On the Move]
- Wednesday, December 12, 2012, 1:50 PM Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the European Journal of Heart Failure which presented data demonstrating that patients with established atrial fibrillation who received ABIO's Gencaro had improvements in heart failure clinical endpoints. The data also showed that Gencaro made it more likely for patients to achieve ventricular rate control, and that Gencaro improved cardiovascular clinical endpoints for those patients who did achieve rate control. Comment! [Healthcare, On the Move, Global & FX]
- Friday, March 26, 2010, 3:27 PM ARCA Biopharma (ABIO +236.6%) shares skyrocket after the company receives a patent protecting its heart-failure treatment methods. (PR) Comment!
-
Brian L. Wilson
$ABIO looks like it's going to have an equity financing soon, I'd be careful about chasing it too soon http://bit.ly/11HHKcF - View all 0 replies
-
- View all 5 replies
-
LEIGHDIST: got hit enough with amrn i don't take a chance anymore anytime i see green i take big or small, i think i will do like you get out on abio
-
LEIGHDIST: Joe ended up selling my portion of abio also at .73 took a gain also but i will go back as soon as it drops hopefully under .50
-
- View all 4 replies
-
joe kelly: There are some naysayers on Stocktwits. Don't know why. More success to you Leigh. -
LEIGHDIST: you to Joe, it will be a long progress but holding on, for one day the fda approval or to complete the phase 3
-
- View all 0 replies
LATEST REPLIES
-
- View all 5 replies
-
LEIGHDIST: got hit enough with amrn i don't take a chance anymore anytime i see green i take big or small, i think i will do like you get out on abio
-
LEIGHDIST: Joe ended up selling my portion of abio also at .73 took a gain also but i will go back as soon as it drops hopefully under .50